Nanomedicines vs. TNBC: Immune System Wake-Up Call 051
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Nanomedicines vs. TNBC: Immune System Wake-Up Call 051
-
Narrado por:
-
De:
In this episode of The Deep Dive, supported by RevGenetics, we explore a groundbreaking shift in oncology: the use of nanomedicine to dismantle the defenses of Triple-Negative Breast Cancer (TNBC). A 2026 scientific review published in Clinical and Translational Medicine introduces STING-activating nanomedicines as "microscopic Trojan horses" designed to turn the tide against one of the most aggressive forms of cancer.
Unlike other breast cancers that have identifiable receptors, TNBC is notoriously "cold"—it effectively wears an invisibility cloak, evading the immune system's natural detection. Les and Amy unpack how these innovative nanocarriers "illuminate" the tumor, triggering the STING pathway to wake up the immune system and initiate a targeted strike. Join us as we discuss how this bridge between nanotechnology and innate immune modulation is paving the way for the next generation of cancer therapy.
Supported by RevGenetics – Science-Based Supplements For Healthy Aging
👉 Explore Longevity Products
Referenced Study:
🔗 Stimulator of interferon genes (STING)-activating nanomedicines: Translating innate immune modulation into effective therapy for triple-negative breast cancer
Hashtags:
#TNBC #CancerResearch #Nanomedicine #Immunotherapy #BreastCancerAwareness #STINGPathway #Oncology #MedicalBreakthrough #TheDeepDive #RevGenetics #ScienceUpdate2026 #TripleNegativeBreastCancer #ImmuneActivation #Nanotechnology #HealthScience #CancerTreatment #InnateImmunity #BioTech #MedicalInnovation #RevGeneticsSupport